Click here to view online. Add this email to your safelist.

AstraZeneca logo

Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

25 November 2025

AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.

Read more  Read more

RSS Feed  RSS Feed Twitter/X  Follow us on X LinkedIn  Follow us on LinkedIn
Legal notice and Terms of Use Privacy policy Cookie policy Site map © AstraZeneca 2025

For more information please visit astrazeneca.com.

If you would like to unsubscribe please click here.